الولايات المتحدة · منصات وبيانات · Morningstar

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

نشره Morningstar · الولايات المتحدة منذ 1 ي

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company…

اقرأ المقال كاملًا على Morningstar سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.morningstar.com)

يستحق القراءة أيضًا

The Motley Fool

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

مشاركة

يستحق القراءة أيضًا

Westinghouse Air Brake Technologies: 3 Key Takeaways for Long-Term Investors

Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances

Kazia gains as Guggenheim is latest to initiate at Buy on lead asset

Medicare is a bargain. What America can’t afford is private health insurance.

Initial jobless claims highlight Thursday’s economic calendar

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge